MedTech

FDA qualifies First AI Tool to Speed MASH Drug Development

The U.S. Food and Drug Administration (FDA) has qualified the first artificial intelligence tool for drug development, specifically AIM-NASH, designed to aid pathologists in evaluating metabolic dysfunction-associated steatohepatitis…